Vassili Valayannopoulos

Company: Decibel Therapeutics Inc.

Job title: Vice President & Head of Clinical Development

Seminars:

Learning from Gene Therapy Treatments in Immunoprivileged Places to Apply Systemically 9:00 am

• Understanding how the immune response is control when minimal • Reviewing clinical findings in eye/ear gene therapy trials • Identifying elements that can be applied to systemic gene therapiesRead more

day: Day Two AM

Comparing Ubiquitous and Specific Promoters and the Effect on Durability 3:30 pm

• Understanding the additional safety concerns associated with ubiquitous promoters • Exploring how to best manipulate promoters to achieve lasting durability • Navigate strategies to better predict promoter selection on durabilityRead more

day: Day Two AM

Strategizing Methods to Circumvent Neutralizing Antibodies and Increase Long Term Durability of Systemically Delivered Gene Therapies 9:05 am

Effective prevention of neutralizing antibodies in gene therapy treatments could be the key to improving durability. However, this is easier said than done and there are several obstacles to overcome for this to become a reality for gene therapies, from identifying patients that would be relevant for that approach to effectively targeting neutralizing antibodies themselves.…Read more

day: Pre-Conference Day